A previous study reported that the traditional chemotherapeutic agent doxorubicin downregulates CIP2A expression, and that increased CIP2A expression confers doxorubicin resistance in breast cancer cells.16 Altogether, these data indicate that CIP2A is overexpressed in MM cell lines at the protein and messenger RNA levels. The gene discussed is CIP2A; the disease is Miyoshi myopathy.